Neuphoria Therapeutics Inc. 8-K

What Happened
Neuphoria Therapeutics (NEUP) filed an 8-K on May 26, 2026 announcing it received an AUD $1,416,026 revenue distribution from its participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC). The payment is related to CTx CRC’s licensing of the KAT6 program to Pfizer following initiation of dosing in the first Phase III trial in ER+/HER2- metastatic breast cancer. The filing notes Neuphoria believes it may be eligible for approximately 4.65% of any future milestone payments from CTx CRC programs (if paid), where the total value to all 17 CTx CRC partners is estimated at USD $460 million.

Key Details

• Received AUD $1,416,026 in 2026 from CTx CRC licensing to Pfizer (KAT6-related, tied to Phase III dosing).
• Company estimates potential entitlement of ~4.65% of future milestone payments from CTx CRC programs, if any; total value to all 17 partners estimated at USD $460M.
• Total CRC trust distributions to Neuphoria since 2016: AUD $3,522,413.68 (includes prior periodic licensing receipts from 2016–2026).
• CTx CRC concluded in December 2020 and evolved into private company Canthera Discovery; Neuphoria (formerly Bionomics Ltd.) was one of 17 partners that contributed to and benefited from CTx CRC licensing activity.

Why It Matters
This 8-K reports a non-operating cash distribution tied to past research and licensing activity rather than product sales or operating revenue. The payment underscores that Neuphoria continues to receive proceeds from legacy collaborations and licensing deals (notably with Pfizer). However, the company is a passive participant and explicitly states it cannot determine whether future milestones will be achieved or the amount of any future payments. The filing also includes standard forward‑looking statement cautions about uncertainty of future outcomes.